Anil Diwan - NanoViricides Chairman and President and Secretary
| NNVC Stock | USD 1.36 0.02 1.45% |
Chairman
Dr. Anil Diwan, Ph.D., was appointed Chairman of the Board, President of the Company September 1, 2018. Dr. Diwan simultaneously therewith and since its formation, has also served as the Chief Executive Officer and Director of AllExcel, Inc. and TheraCour Pharma, Inc. and is the original inventor of the technologies licensed to NanoViricides Inc., as well as the TheraCour polymeric micelle technologies and products based on them. Since 1992, he has researched and developed TheraCour nanomaterials. Dr. Diwan was the first to propose the development of novel pendant polymers for drug delivery that led to an explosion of research in pharmacological applications of polymeric micelles. Anil has won over 12 NIH SBIR grants. Dr. Diwan holds several issued patents, and three PCT international patent applications in various stages of prosecution in a number of countries, and, and has made intellectual property depositions of several additional patentable discoveries with the patent attorney since 2018.
| Age | 65 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 1 Controls Drive, Shelton, CT, United States, 06484 |
| Phone | 203 937 6137 |
| Web | https://www.nanoviricides.com |
Anil Diwan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Anil Diwan against NanoViricides stock is an integral part of due diligence when investing in NanoViricides. Anil Diwan insider activity provides valuable insight into whether NanoViricides is net buyers or sellers over its current business cycle. Note, NanoViricides insiders must abide by specific rules, including filing SEC forms every time they buy or sell NanoViricides'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Anil Diwan over a month ago Disposition of 94471 shares by Anil Diwan of NanoViricides subject to Rule 16b-3 | ||
Anil Diwan over six months ago Disposition of 94471 shares by Anil Diwan of NanoViricides subject to Rule 16b-3 |
NanoViricides Management Efficiency
The company has return on total asset (ROA) of (0.3581) % which means that it has lost $0.3581 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.63) %, meaning that it created substantial loss on money invested by shareholders. NanoViricides' management efficiency ratios could be used to measure how well NanoViricides manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.7. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, NanoViricides' Intangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 22 M, whereas Non Current Assets Total are forecasted to decline to about 6.8 M.Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.36 |
NanoViricides Management Team
Elected by the shareholders, the NanoViricides' board of directors comprises two types of representatives: NanoViricides inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NanoViricides. The board's role is to monitor NanoViricides' management team and ensure that shareholders' interests are well served. NanoViricides' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NanoViricides' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Randall Barton, Chief Officer | ||
| Anil Diwan, Chairman and President and Secretary | ||
| BS MBA, Chief Officer |
NanoViricides Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NanoViricides a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 14.04 M | ||||
| Shares Outstanding | 13.95 M | ||||
| Shares Owned By Insiders | 4.07 % | ||||
| Shares Owned By Institutions | 9.72 % | ||||
| Number Of Shares Shorted | 295.1 K | ||||
| Price To Earning | (6.02) X | ||||
| Price To Book | 1.93 X | ||||
| EBITDA | (7.76 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Return On Assets (0.36) | Return On Equity (0.63) |
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.